Corbus Pharmaceuticals Holdings Valuation
Is CRBP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CRBP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CRBP's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CRBP's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CRBP?
Other financial metrics that can be useful for relative valuation.
| What is CRBP's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$391.39m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -8.8x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does CRBP's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.6x | ||
LXRX Lexicon Pharmaceuticals | 4.4x | 37.5% | US$379.2m |
VSTM Verastem | 4.4x | 49.6% | US$252.6m |
SVRA Savara | 4.9x | 51.5% | US$632.8m |
ABOS Acumen Pharmaceuticals | 0.7x | -13.5% | US$193.5m |
CRBP Corbus Pharmaceuticals Holdings | n/a | -19.1% | US$391.4m |
Price-To-Book vs Peers: CRBP has negative equity and a Price-To-Book Ratio (-56.7x) compared to the peer average (3.6x).
Price to Earnings Ratio vs Industry
How does CRBP's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: CRBP has negative equity and a Price-To-Book Ratio (-56.7x) compared to the US Biotechs industry average (2.1x).
Price to Book Ratio vs Fair Ratio
What is CRBP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -56.7x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate CRBP's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$37.25 | US$55.00 +47.7% | 5.5% | US$58.00 | US$52.00 | n/a | 2 |
| Apr ’25 | US$37.99 | US$55.00 +44.8% | 5.5% | US$58.00 | US$52.00 | n/a | 2 |
| Oct ’24 | US$6.74 | US$13.00 +92.9% | 69.2% | US$22.00 | US$4.00 | n/a | 2 |
| Sep ’24 | US$6.65 | US$13.00 +95.5% | 69.2% | US$22.00 | US$4.00 | n/a | 2 |
| Aug ’24 | US$7.24 | US$13.00 +79.6% | 69.2% | US$22.00 | US$4.00 | n/a | 2 |
| Jul ’24 | US$7.84 | US$13.00 +65.8% | 69.2% | US$22.00 | US$4.00 | n/a | 2 |
| Jun ’24 | US$9.79 | US$13.00 +32.8% | 69.2% | US$22.00 | US$4.00 | n/a | 2 |
| Mar ’24 | US$2.80 | US$105.00 +3,650.0% | 14.3% | US$120.00 | US$90.00 | US$35.00 | 2 |
| Feb ’24 | US$4.92 | US$66.00 +1,242.3% | 36.4% | US$90.00 | US$42.00 | US$27.79 | 2 |
| Jan ’24 | US$3.32 | US$66.00 +1,891.0% | 36.4% | US$90.00 | US$42.00 | US$6.04 | 2 |
| Dec ’23 | US$4.54 | US$66.00 +1,354.1% | 36.4% | US$90.00 | US$42.00 | US$6.50 | 2 |
| Nov ’23 | US$3.99 | US$66.00 +1,554.1% | 36.4% | US$90.00 | US$42.00 | US$5.05 | 2 |
| Oct ’23 | US$4.95 | US$66.00 +1,233.3% | 36.4% | US$90.00 | US$42.00 | US$6.74 | 2 |
| Sep ’23 | US$5.80 | US$66.00 +1,038.7% | 36.4% | US$90.00 | US$42.00 | US$6.65 | 2 |
| Aug ’23 | US$7.59 | US$66.00 +769.9% | 36.4% | US$90.00 | US$42.00 | US$7.24 | 2 |
| Jul ’23 | US$7.75 | US$66.00 +751.7% | 36.4% | US$90.00 | US$42.00 | US$7.84 | 2 |
| Jun ’23 | US$9.00 | US$66.00 +633.6% | 36.4% | US$90.00 | US$42.00 | US$9.79 | 2 |
| May ’23 | US$10.16 | US$66.00 +549.5% | 36.4% | US$90.00 | US$42.00 | US$8.48 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.